Activity
Mon
Wed
Fri
Sun
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
What is this?
Less
More

Memberships

Cancer Warriors Vault

53 members • Free

Cancer Warriors

480 members • Free

541 contributions to Cancer Warriors
John Hopkins New Mebendazole Patient
https://www.facebook.com/share/p/1CU1QfHe5u/ Johns Hopkins’ New Mebendazole Patent and Its Significance for Cancer Therapeutics A recent public news article has highlighted a development that deserves serious attention within oncology and drug-repurposing research: Johns Hopkins scientists have patented a new crystalline form of mebendazole—referred to as polymorph C—designed to enhance its anti-cancer properties. Background: Why Mebendazole Matters Mebendazole is a benzimidazole-class anthelmintic with a well-characterised safety profile accumulated over ~40 years of clinical use. Beyond its antiparasitic activity, numerous preclinical studies have demonstrated: Microtubule inhibition in cancer cells Disruption of glucose metabolism in malignant tissues Interference with multiple signalling pathways (Hh, Wnt/β-catenin, Bcl-2) Selective cytotoxicity to tumour cells at concentrations tolerated by normal cells Despite these properties, clinical adoption has been limited largely because the original molecule is off-patent, making large-scale commercial trials financially unviable. What Johns Hopkins Has Patented The new patent centers on: Polymorph C — a redesigned crystalline form This form appears to demonstrate: Improved oral absorption Higher plasma concentrations Prolonged systemic exposure Greater potency in killing cancer cells in vitro compared with existing polymorphs This is scientifically notable, because mebendazole traditionally suffers from: Poor gastrointestinal absorption High inter-individual variability Low bioavailability unless taken with high-fat meals A more bioavailable crystalline form directly addresses these limitations. Synergy Through Transporter Inhibition The Johns Hopkins team also referenced co-administration with elacridar, a potent inhibitor of: P-glycoprotein (P-gp) Breast Cancer Resistance Protein (BCRP) These efflux pumps are responsible for removing chemotherapeutic agents from cancer cells.
My wife passed
My wife passed on August 2 after a whole month in Hospice, she fought cancer for only 6 months,, her diagnose late January and her death in august,,,,,,,her cancer went to her brain and in a matter of two weeks she was in hospice,,,,, those who need radiation for the brain please please, think about it twice,,,, after 4 radiation treatments she went down from there,,,,,,,, just wanted to thank everyone here and to wish you strength, cure and health, I pray Gof will lead you and give you mercy, I hope we can find or establish a cure to this horrible disease one day,, With Love Jose
0 likes • 15d
So very sorry for your loss. May you find comfort in that which gives you peace.
Thank you Everyone!
My Father after fighting for more than three years with immense energy and will to live passed away two weeks back. I won’t be able to say much but thank you everyone & lot of positive energy to everyone who is in this journey to defeat this disease. 🙏🏻
1 like • 28d
I'm so sorry for your loss. Sending love and prayers.
Group Call
Is there no one joining the group call?
2 likes • Nov 3
I tried to get on but we were having internet connection issues. So sorry.
1-10 of 541
Kimberly Smith
7
3,941points to level up
@kimberly-smith-9194
TNBC-Metastatic to bone dx 8/2023; original dx Triple Positive Bilateral Breast Cancer presented simultaneously 5/2010.

Active 3d ago
Joined Sep 24, 2024
ESTJ
DFW, Texas
Powered by